Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

@article{Dodick2014SafetyAE,
  title={Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial},
  author={D. Dodick and P. Goadsby and S. Silberstein and R. Lipton and J. Olesen and M. Ashina and K. Wilks and D. Kudrow and R. Kroll and B. Kohrman and R. Bargar and J. Hirman and Jeffrey T. L. Smith},
  journal={The Lancet Neurology},
  year={2014},
  volume={13},
  pages={1100-1107}
}
BACKGROUND Calcitonin gene-related peptide (CGRP) is crucial in the pathophysiology of migraine. We assessed the safety, tolerability, and efficacy of ALD403, a genetically engineered humanised anti-CGRP antibody, for migraine prevention. METHODS In this randomised, double-blind, placebo-controlled, exploratory, proof-of-concept phase 2 trial, patients aged 18-55 years with five to 14 migraine days per 28-day period were randomly assigned (1:1) via an interactive web response system to… Expand
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
TLDR
In patients with chronic migraine, erenumab 70 mg and 140 mg reduced the number of monthly migraine days with a safety profile similar to placebo, providing evidence that erenUMab could be a potential therapy for migraine prevention. Expand
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
TLDR
It is suggested that AMG 334 70 mg might be a potential therapy for migraine prevention in patients with episodic migraine and support further investigation of AMG334 in larger phase 3 trials. Expand
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
TLDR
TEV-48125, at doses of 225 mg and 675 mg given once every 28 days for 12 weeks, was safe, well tolerated, and effective as a preventive treatment of high-frequency episodic migraine, thus supporting advancement of the clinical development programme to phase 3 clinical trials. Expand
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
TLDR
It is demonstrated that eptinezumab appears effective and well-tolerated for the preventive treatment of chronic migraine and justifies the conduct of pivotal phase 3 trials for migraine prevention. Expand
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial
TLDR
Across the 12-week treatment period, all five atogepant groups showed significant least-squares mean (SE) change from baseline in mean monthly migraine days across 12 weeks of treatment using a modified intention-to-treat approach. Expand
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
TLDR
Efficacy endpoints were change from baseline in the number of headache-hours during the third treatment cycle (weeks 9-12) and safety and tolerability during the study, thus supporting the further development of TEV-48125 for the preventive treatment of chronic migraine in a phase 3 trial. Expand
Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies
TLDR
All four CGRP antibodies display comparable efficacy that does not differ significantly from that of the currently available oral antimigraine drugs, however, their safety and tolerability profiles as well as low frequency of administration looks promising but remains to be verified in long-term and large-scale trials. Expand
The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis
TLDR
Based on the results of this meta-analysis, CGRP monoclonal antibodies significantly reduced the monthly migraine days and acute migraine-specific medication and were effective and safe for preventive treatment of episodic migraine. Expand
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
TLDR
The current body of evidence reveals that CGRP mAb is an effective and safe preventive treatment for episodic migraine. Expand
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
TLDR
Eptinezumab 100 mg or 300’mg administered IV at day 0 and repeated at week 12 provided sustained migraine preventive benefit over a full 24 weeks and demonstrated an acceptable safety profile in patients with chronic migraine. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
TLDR
Preliminary evidence is provided that LY2951742 might be beneficial in migraine prevention and support for the role of calcitonin gene-related peptide in the pathogenesis of migraine is provided. Expand
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
TLDR
Telcagepant 300 mg is effective as an acute treatment for migraine with efficacy comparable to that of zolmitriptan 5 mg, but with fewer associated adverse effects. Expand
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.
TLDR
The CGRP antagonist BIBN 4096 BS was effective in treating acute attacks of migraine and showed significant superiority over placebo with respect to most secondary end points. Expand
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study
TLDR
Efficacy of BI 44370 TA was shown in a dose-dependent manner in the treatment of acute migraine attacks, and the frequency of adverse events was low in all groups. Expand
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
TLDR
The role of CGRP in the pathophysiology of migraine and the various treatment modalities that are currently available to target this neuropeptide are discussed. Expand
New drugs in migraine treatment and prophylaxis: telcagepant and topiramate
TLDR
Data suggest that topiramate could aid reversion of chronic migraine to episodic migraine, and Telcagepant might provide hope for those who have a poor response to, or are unable to use, older drugs. Expand
Possible sites of action of the new calcitonin gene-related peptide receptor antagonists
TLDR
The aim of this paper is to review recent localization studies of CGRP and its receptor components within the nervous system and to discuss whether these sites could be possible targets for the C GRP-receptor antagonists. Expand
Sumatriptan Reverses the Changes in Calcitonin Gene-Related Peptide Seen in the Headache Phase of Migraine
TLDR
The effect of parentral administration of sumatriptan on neuropeptide levels in the cranial vessels during migraine is examined. Expand
Factors Associated With The Prophylactic Effect of Placebo Injections in Subjects Enrolled in a Study of Botulinum Toxin For Migraine
TLDR
Male gender, opioid use and injections in the neck/shoulders are associated with placebo prophylaxis, and these findings may have important implications for the design of future clinical trials and for the clinical management of migraineurs. Expand
Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura
TLDR
Data indicate similar neurobiological pathways responsible for triggering migraine headache in MA and MO patients, and suggest differences between MA/MO and FHM. Expand
...
1
2
3
4
...